NCT05737199View on ClinicalTrials.gov

Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
Ovarian Squamous Cell Carcinoma
Interventions
DRUG

MK-3475 (pembrolizumab)

MK-3475 (pembrolizumab) 200mg IV every 3 weeks \[Q3W\] Treated for 2 years (35 cycles), or until PD, unacceptable toxicity, or study withdrawal.

Trial Locations (1)

951-8510

RECRUITING

Niigata University Medical & Dental Hosptal, Niigata

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Niigata University Medical & Dental Hospital

OTHER

NCT05737199 - Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter